Hepatic artery thrombosis and use of anticoagulants and antiplatelet agents in pediatric liver transplantation
Pediatric Transplantation · 2024
DOI: 10.1111/petr.14516 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, 2024. Verfasst von Keith Feldman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Health Outcomes and Health Services Research, Children's Mercy Kansas City, University of Missouri-Kansas City School of Medicine, Kansas City, Misso…. Hauptthemen laut MEDLINE: Liver Transplantation, Liver Diseases, Thrombosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
Hepatic artery thrombosis (HAT) is a reported complication of 5%–10% of pediatric liver transplantations, rates 3–4 times that seen in adults. Early HAT (seen within 14 days after transplant) can lead to severe allograft damage and possible urgent re‐transplantation. In this report, we present our analysis of HAT in pediatric liver transplant from a national clinical database and examine the association of HAT with anticoagulant or antiplatelet medication administered in the post‐operative period.
Methods
Data were obtained from the Pediatric Health Information System database maintained by the Children's Hospital Association. For each liver transplant recipient identified in a 10‐year period, diagnosis, demographic, and medication data were collected and analyzed.
Results
Our findings showed an average rate of HAT of 6.3% across 31 centers. Anticoagulant and antiplatelet medication strategies varied distinctly among and even within centers, likely due to the fact there are no consensus guidelines. Notably, in centers with similar medication usage, HAT rates continue to vary. At the patient level, use of aspirin within the first 72 h of transplantation was associated with a decreased risk of HAT, consistent with other reports in the literature.
Conclusion
We suggest that concerted efforts to standardize anticoagulation approaches in pediatric liver transplant may be of benefit in the prevention of HAT. A prospective multi‐institutional study of regimen—possibly including aspirin—following transplantation could have significant value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Outcomes and Health Services Research, Children's Mercy Kansas City, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
- Department of Pharmacy, Children's Mercy Kansas City, University of Missouri-Kansas City School of Pharmacy, Kansas City, Missouri, USA.
- Department of Surgery, Children's Mercy Kansas City, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
- Division of Gastroenterology, Children's Mercy Kansas City, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
ORCID-Profile: Keith Feldman, Richard J Hendrickson, Ryan T Fischer
Zitieren
APA
Feldman, K., Heble, D. E., Hendrickson, R. J., & Fischer, R. T. (2024). Hepatic artery thrombosis and use of anticoagulants and antiplatelet agents in pediatric liver transplantation. Pediatric Transplantation. https://doi.org/10.1111/petr.14516
Vancouver
Feldman K, Heble DE, Hendrickson RJ, Fischer RT. Hepatic artery thrombosis and use of anticoagulants and antiplatelet agents in pediatric liver transplantation. Pediatric Transplantation. 2024. doi:10.1111/petr.14516
BibTeX
@article{Feldman2024,
author = {Feldman, Keith and Heble, Daniel E and Hendrickson, Richard J and Fischer, Ryan T},
title = {Hepatic artery thrombosis and use of anticoagulants and antiplatelet agents in pediatric liver transplantation},
journal = {Pediatric Transplantation},
year = {2024},
doi = {10.1111/petr.14516}
}
EUVIMED